PURPOSE: The primary objective of this retrospective analysis is to assess efficacy and @entity137 of a chemotherapeutic regimen using weekly @entity3003 in combination with weekly @entity1311 as first-line therapy for advanced/metastatic @entity1149 ( @entity1149 ). METHODS: All @entity1 with stage IIIB/IV @entity1149 treated with weekly @entity3003 AUC (area under the curve) 3 days 1, 8, 15, q4w in combination with weekly @entity1311 75  mg/m(2) days 1, 8, 15, q4w as first-line therapy at the Kantonsspital Graubuenden between August 2004 and May 2014 were retrospectively analyzed by medical record review. RESULTS: A total of 90 @entity1 were treated. Median age was 66  years (range 39-88). A total of 229 chemotherapy cycles were administered. Hematological and non-hematological @entity137 were acceptable allowing for a median relative dose intensity for all planned treatment cycles of 76  %. Overall response rate was 34  %. Median overall and progression free survival was 6.3 (95  % CI, 4.9-8.7) and 3.4 (95  % CI, 2.3-5.1) months, respectively. @entity1 with an ECOG performance score (PS) of 0 or 1 had a significantly better @entity3012 compared to @entity1 with a PS of >= 2. No statistically significant difference was observed in @entity1 younger or older than 70  years of age. CONCLUSIONS: Weekly @entity3003 in combination with weekly @entity1311 results in good response rates and acceptable @entity137 in @entity1 with advanced and metastatic @entity1149 including @entity1 with poor risk features (brain metastases, older age, and impaired PS). Nonetheless, selecting the right @entity1 for a @entity902 -based combination treatment remains an important task in clinical practice.

Weekly @entity3003 in combination with weekly XXXX in the treatment of metastatic @entity1149 : a single center 10-year experience.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity3012 :: ('MESH:C567932', 'Disease') :: ['OS'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']
@entity1311 :: (MESH:D017239,Chemical) :: ['paclitaxel']
